00:32 , Jun 11, 2016 |  BC Extra  |  Company News

Eagle soars after bendamustine patent ruling

A judge in the U.S. District Court for the District of Delaware upheld most claims of a patent from the Cephalon Inc. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) covering cancer drug Treanda bendamustine. Eagle...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the...
02:11 , Dec 9, 2015 |  BC Extra  |  Company News

FDA approves Bendeka for CLL, NHL

FDA approved Bendeka bendamustine RTD ( EP-3102) from Teva Pharmaceutical Industries Inc. (NYSE:TEVA) and Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) to treat chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphoma that has progressed during or within...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Event planner

For investors who are not inclined to sit it out until the volatility abates, the fourth quarter is bursting with late-stage catalysts. There are no fewer than 17 PDUFA dates on the calendar before year...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Big news

The performance of big cap biotechs has lagged that of companies one tier down, but the second half includes a host of milestones that could put the bellwethers on a steeper upward trajectory. Buysiders...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Bendamustine RTD regulatory update

FDA accepted for review an NDA for EP-3102 to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a...
01:37 , Feb 18, 2015 |  BC Extra  |  Company News

Eagle lands deal with Teva for EP-3102

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) gained $5.12 (24%) to $26.10 after it granted Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) exclusive rights to commercialize EP-3102 in the U.S. Eagle submitted an NDA to FDA last week for EP-3102...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

4Q14 Financial Markets Preview: Commercial race in HCV

HCV and cancer immunotherapy again top the list of milestones in 4Q14, as investors expect approval of three new HCV regimens plus clinical data for combos looking to challenge Gilead Sciences Inc. and AbbVie Inc....
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Bendamustine RTD regulatory update

Eagle said FDA granted Orphan Drug designation to EP-3102 to treat chronic lymphocytic leukemia (CLL) and indolent B cell non-Hodgkin’s lymphoma (NHL). EP-3102 is a ready-to-dilute (RTD) formulation of bendamustine to be administered by infusion...